Humana’s CenterWell pharmacy has announced a new program in collaboration with Eli Lilly and Company to dispense GLP-1 weight loss drugs as part of an initiative to help employers assist their employees in managing obesity. This initiative was discussed by Humana CEO Jim Rechtin at the Forbes Healthcare Summit in New York, where he emphasized the importance of improving the patient pharmacy experience.
The program, which aims to streamline the prescription process and enhance access to medications for patients, reflects Humana’s transition into a “consumer healthcare company” under Rechtin’s leadership. CenterWell Pharmacy will serve as a dispensing pharmacy for eligible patients participating in approved employer plan-sponsored obesity management programs, working closely with designated third-party organizations to ensure prescription fulfillment and delivery.
Eli Lilly manufactures the GLP-1 weight loss drugs Zepbound and Mounjaro, which will be available through this program. Kevin Hern, Senior Vice President of Lilly’s Employer unit, stated that employers are keen on supporting their employees’ health but often face challenges in providing coverage for obesity management medicines. Humana pharmacy president Bethanie Stein highlighted the success of CenterWell Pharmacy in expanding access to obesity management medications at more affordable price points through direct-to-patient distribution.
Last year, CenterWell Pharmacy ventured into the direct-to-patient specialty pharmacy sector, catering to the increasing demand for popular GLP-1 weight loss drugs. Stein emphasized the potential for distributing these medications through innovative employer-based programs, emphasizing the importance of a sustainable approach to providing valuable weight loss medications.
The collaboration between Humana’s CenterWell pharmacy and Eli Lilly signifies a step towards revolutionizing the healthcare system by making essential medications more accessible and affordable. This partnership underscores Humana’s commitment to enhancing healthcare access and affordability, ultimately aiming to improve the overall well-being of individuals struggling with obesity.
